Breaking News, Financial News

Financial Report: ImClone Systems 1Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ImClone Systems  1Q Revenues: $162.6 million (+15%) 1Q Loss: $55.9 million (earnings were $28.8 million in 1Q08) Comments: Erbitux sales were $417.3 million (+12%). Royalty revenue related to Erbitux was $95.0 million (+24%). License fees and milestone revenue was $24.1 million (-18%). This decrease was due to the amended agreement with BMS for the co-development and co-commercialization for Erbitux in North America. Manufacturing revenue was $25.4 million (+54%) due to increased deman...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters